Cipla profit and loss

Latest FY26

Revenue: ₹28,163cr+2.2% on FY25
EBITDA: ₹5,883cr−17.5% on FY25
Net profit: ₹3,862cr−26.7% on FY25
EPS: ₹48.03−26.4% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	28,139	28,163	27,548	25,774	22,753	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	717	882	862	747	475
	28,855	29,045	28,409	26,521	23,229
	5,725	5,842	5,410	5,221	5,520
	5,098	4,451	3,851	3,536	2,829
	−641	−744	−332	63.0	−96.0
	5,711	5,366	4,833	4,310	3,830
	60.9	54.4	62.0	89.9	110
	1,310	1,211	1,107	1,051	1,172
	7,456	7,364	6,658	6,353	5,644
	24,720	23,545	21,589	20,624	19,008
	4,790	5,883	7,128	6,291	5,027
	3,480	4,672	6,021	5,240	3,855
Profit
	4,135	5,500	6,821	5,897	4,221
	−276	−276	0.0	−195	−182
	3,859	5,224	6,821	5,702	4,038
	1,208	1,441	1,708	1,697	1,265
	−217	−87.1	−179	−150	−61.9
	991	1,354	1,530	1,547	1,203
	−14.5	−8.1	−21.9	−1.6	−2.6
	2,854	3,862	5,269	4,154	2,833
	2,868	3,870	5,291	4,155	2,835
	668	688	219	−121	138
	3,522	4,549	5,488	4,033	2,971
	2,897	3,879	5,273	4,122	2,802
	−43.2	−17.5	−3.3	32.2	31.0
Per share
	₹35.87	₹48.03	₹65.29	₹51.05	₹34.72
	₹35.83	₹48.00	₹65.24	₹51.01	₹34.69
Other comprehensive income — detail
	668	688	219	—	—
	−158	−189	−66.1	−88.6	0.6
	5.7	−2.1	−9.9	−27.7	−2.1
	—	—	—	−27.7	−2.1
	840	828	276	−58.6	137
	8.4	−46.5	1.3	1.1	2.4
	—	—	—	1.1	2.4
	3,567	4,568	5,489	3,998	2,930
	−45.1	−18.4	−1.6	35.4	40.0
Per share — as-filed variants
	₹35.87	₹48.03	₹65.29	₹51.05	₹34.72
	₹35.83	₹48.00	₹65.24	₹51.01	₹34.69
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	17,957	18,613	18,619	16,955	14,501
	63.8%	66.1%	67.6%	65.8%	63.7%
Adjusted (ex-exceptional items) — derived
	4,135	5,500	6,821	5,897	4,221
	−276	−276	0.0	−195	−182
	3,059	4,066	5,269	4,296	2,961
	₹38.45	₹50.57	₹65.29	₹52.79	₹36.29

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

CIPLA₹1,365.60

Cipla Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersSUNPHARMA DRREDDY LUPIN APOLLOHOSP MAXHEALTH DIVISLAB TORNTPHARM ZYDUSLIFEMcap ₹1.10L Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	22,753.1	25,774.1	27,547.6	28,162.6	28,138.9
Other Income	475.5	746.6	861.9	882.0	716.6
Total Income	23,228.6	26,520.7	28,409.5	29,044.6	28,855.5
Expenses
+ Cost of Materials Consumed	5,519.6	5,220.5	5,409.6	5,841.6	5,724.8
+ Purchases of Stock-in-Trade	2,828.7	3,536.0	3,851.5	4,451.4	5,097.7
+ Changes in Inventories	-96.0	63.0	-332.1	-743.9	-640.8
+ Employee Benefit Expense	3,830.1	4,310.0	4,832.8	5,366.3	5,711.3
+ Finance Costs	109.5	89.9	62.0	54.4	60.9
+ Depreciation & Amortisation	1,172.1	1,051.0	1,107.0	1,211.0	1,310.4
+ Other Expenses	5,643.8	6,353.4	6,657.9	7,364.3	7,455.9
Total Expenses	19,007.8	20,623.9	21,588.7	23,545.1	24,720.1
EBITDA	5,027.0	6,291.1	7,127.9	5,882.9	4,790.1
EBIT	3,854.9	5,240.0	6,021.0	4,671.9	3,479.7
Profit
PBT before Exceptional Items	4,220.8	5,896.7	6,820.8	5,499.5	4,135.4
+ Exceptional Items	-182.4	-194.8	0.0	-275.9	-275.9
Pretax Income	4,038.4	5,701.9	6,820.8	5,223.6	3,859.4
+ Current Tax	1,264.8	1,696.8	1,708.4	1,441.0	1,208.1
+ Deferred Tax	-61.9	-150.3	-178.6	-87.1	-217.0
Tax Expense	1,202.9	1,546.6	1,529.8	1,353.8	991.2
+ Share of Associates & JVs	-2.6	-1.6	-21.9	-8.1	-14.5
Net Income	2,832.9	4,153.7	5,269.2	3,861.7	2,853.8
+ Net Income — Continuing Ops	2,835.5	4,155.3	5,291.1	3,869.8	2,868.3
+ Other Comprehensive Income	137.6	-120.6	218.7	687.7	668.3
Total Comprehensive Income	2,970.5	4,033.1	5,487.9	4,549.5	3,522.1
Net Income to Common	2,801.9	4,121.6	5,272.5	3,879.2	2,897.0
Minority Interest	31.0	32.2	-3.3	-17.5	-43.2
Per Share
Basic EPS	34.72	51.05	65.29	48.03	35.87
Diluted EPS	34.69	51.01	65.24	48.00	35.83
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	218.7	687.7	668.3
+ Items NOT to be Reclassified to P&L	0.6	-88.6	-66.1	-188.9	-158.1
+ Tax on Items NOT to be Reclassified	-2.1	-27.7	-9.9	-2.1	5.7
+ Tax on Items NOT to be Reclassified — alt tag	-2.1	-27.7	—	—	—
+ Items to be Reclassified to P&L	137.4	-58.6	276.2	828.1	840.5
+ Tax on Items to be Reclassified	2.4	1.1	1.3	-46.5	8.4
+ Tax on Items to be Reclassified — alt tag	2.4	1.1	—	—	—
Comprehensive Income — Owners of Parent	2,930.5	3,997.7	5,489.5	4,567.9	3,567.1
Comprehensive Income — Non-controlling Interests	40.0	35.4	-1.6	-18.4	-45.1
Per Share — as-filed variants
Basic EPS — Continuing Operations	34.72	51.05	65.29	48.03	35.87
Diluted EPS — Continuing Operations	34.69	51.01	65.24	48.00	35.83
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	14,500.8	16,954.5	18,618.6	18,613.5	17,957.2
Gross Margin %	63.73	65.78	67.59	66.09	63.82
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	4,220.8	5,896.7	6,820.8	5,499.5	4,135.4
− Exceptional Items (reconciliation)	-182.4	-194.8	0.0	-275.9	-275.9
Net Income Adj (tax-effected)	2,961.0	4,295.7	5,269.2	4,066.1	3,058.9
EPS Adj	36.29	52.79	65.29	50.57	38.45
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	161.4	161.5	161.5	161.6	161.6

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 146%.